# Icosabutate - A Phase I, Single Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects

> **NCT02364635** · PHASE1 · COMPLETED · sponsor: **Pronova BioPharma** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** icosabutate

## Key facts

- **NCT ID:** NCT02364635
- **Lead sponsor:** Pronova BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2015-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02364635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02364635, "Icosabutate - A Phase I, Single Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02364635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*